Search

Your search keyword '"Mac Manus, Michael"' showing total 140 results
Start Over Author "Mac Manus, Michael"
140 results on '"Mac Manus, Michael"'

1. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG

Author

Brady, Jessica L., Binkley, Michael S., Hajj, Carla, Chelius, Monica, Chau, Karen, Balogh, Alex, Levis, Mario, Filippi, Andrea Riccardo, Jones, Michael, Mac Manus, Michael, Wirth, Andrew, Oguchi, Masahiko, Vistisen, Anders Krog, Andraos, Therese Youssef, Ng, Andrea K., Aleman, Berthe M.P., Choi, Seo Hee, Kirova, Youlia, Hardy, Sara, Reinartz, Gabriele, Eich, Hans T., Bratman, Scott V., Constine, Louis S., Suh, Chang-Ok, Dabaja, Bouthaina, El-Galaly, Tarec C., Hodgson, David C., Ricardi, Umberto, Yahalom, Joachim, Hoppe, Richard T., and Mikhaeel, N. George

Published
2019
Full Text
View/download PDF

8. Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group

Author

Qi, Shu-Nan, primary, Li, Ye-Xiong, additional, Specht, Lena, additional, Oguchi, Masahiko, additional, Tsang, Richard, additional, Ng, Andrea, additional, Suh, Chang-Ok, additional, Ricardi, Umberto, additional, Mac Manus, Michael, additional, Dabaja, Bouthaina, additional, and Yahalom, Joachim, additional

Published
2021
Full Text
View/download PDF

9. Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma:Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group

Author

Qi, Shu Nan, Li, Ye Xiong, Specht, Lena, Oguchi, Masahiko, Tsang, Richard, Ng, Andrea, Suh, Chang Ok, Ricardi, Umberto, Mac Manus, Michael, Dabaja, Bouthaina, Yahalom, Joachim, Qi, Shu Nan, Li, Ye Xiong, Specht, Lena, Oguchi, Masahiko, Tsang, Richard, Ng, Andrea, Suh, Chang Ok, Ricardi, Umberto, Mac Manus, Michael, Dabaja, Bouthaina, and Yahalom, Joachim

Abstract

In the multidisciplinary management of early-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTCL), with curative intent, radiation therapy is the most efficacious modality and is an essential component of a combined-modality regimen. In the past decade, utilization of upfront radiation therapy and non–anthracycline-based chemotherapy has improved treatment and prognosis. This guideline mainly addresses the heterogeneity of clinical features, principles of risk-adapted therapy, and the role and appropriate design of radiation therapy. Radiation therapy methods (including target volume definition, dose and delivery methods) are crucial for optimizing cure for patients with early-stage ENKTCL. The application of the principles of involved site radiation therapy in this lymphoma entity often leads to a more extended clinical target volume (CTV) than in other lymphoma types because it usually presents with primary tumor invasion, multifocal lesions, or extensive submucosal infiltration beyond the macroscopic disease. The CTV varies across different primary sites and is classified mainly into nasal, nonnasal upper aerodigestive tract (UADT), and extra-UADT entities. This review is a consensus of the International Lymphoma Radiation Oncology Group regarding the approach to radiation therapy, target-volume definition, optimal dose, and dose constraints in ENKTCL treatment.

Published
2021

19. What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non–Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?

Author

Turgeon, Guy-Anne, primary, Iravani, Amir, additional, Akhurst, Tim, additional, Beaulieu, Alexis, additional, Callahan, Jason W., additional, Bressel, Mathias, additional, Cole, Aidan J., additional, Everitt, Sarah J., additional, Siva, Shankar, additional, Hicks, Rodney J., additional, Ball, David L., additional, and Mac Manus, Michael P., additional

Published
2018
Full Text
View/download PDF

20. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival

Author

Everitt, Sarah, primary, Ball, David, additional, Hicks, Rodney J., additional, Callahan, Jason, additional, Plumridge, Nikki, additional, Trinh, Jenny, additional, Herschtal, Alan, additional, Kron, Tomas, additional, and Mac Manus, Michael, additional

Published
2017
Full Text
View/download PDF

49. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.

Author

Everitt S, Hicks RJ, Ball D, Kron T, Schneider-Kolsky M, Walter T, Binns D, Mac Manus M, Everitt, Sarah, Hicks, Rodney J, Ball, David, Kron, Tomas, Schneider-Kolsky, Michal, Walter, Tania, Binns, David, and Mac Manus, Michael

Abstract

Purpose: To establish whether (18)F-3'-deoxy-3'-fluoro-L-thymidine ((18)F-FLT) can monitor changes in cellular proliferation of non-small-cell lung cancer (NSCLC) during radical chemo-radiotherapy (chemo-RT). Methods and Materials: As part of a prospective pilot study, 5 patients with locally advanced NSCLC underwent serial (18)F-FLT positron emission tomography (PET)/computed tomography (CT) scans during treatment. Baseline (18)F-FLT PET/CT scans were compared with routine staging (18)F-FDG PET/CT scans. Two on-treatment (18)F-FLT scans were performed for each patient on Days 2, 8, 15 or 29, providing a range of time points for response assessment. Results: In all 5 patients, baseline lesional uptake of (18)F-FLT on PET/CT corresponded to staging (18)F-FDG PET/CT abnormalities. (18)F-FLT uptake in tumor was observed on five of nine (55%) on-treatment scans, on Days 2, 8 and 29, but not Day 15. A "flare" of (18)F-FLT uptake in the primary tumor of one case was observed after 2 Gy of radiation (1.22 x baseline). The remaining eight on-treatment scans demonstrated a mean reduction in (18)F-FLT tumor uptake of 0.58 x baseline. A marked reduction of (18)F-FLT uptake in irradiated bone marrow was observed for all cases. This reduction was observed even after only 2 Gy, and all patients demonstrated a complete absence of proliferating marrow after 10 Gy. Conclusions: This proof of concept study indicates that (18)F-FLT uptake can monitor the distinctive biologic responses of epithelial cancers and highly radiosensitive normal tissue changes during radical chemo-RT. Further studies of (18)F-FLT PET/CT imaging during therapy may suggest that this tracer is useful in developing response-adapted RT for NSCLC. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

50. What 18 F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?

Author

Turgeon GA, Iravani A, Akhurst T, Beaulieu A, Callahan JW, Bressel M, Cole AJ, Everitt SJ, Siva S, Hicks RJ, Ball DL, and Mac Manus MP

Subjects
Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Female, Humans, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Male, Middle Aged, Survival Analysis, Treatment Outcome, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Carcinoma, Non-Small-Cell Lung therapy, Chemoradiotherapy, Fluorodeoxyglucose F18, Lung Neoplasms diagnostic imaging, Lung Neoplasms therapy, Positron Emission Tomography Computed Tomography
Abstract

The optimal methodology for defining response with 18 F-FDG PET after curative-intent chemoradiation for non-small cell lung cancer (NSCLC) is unknown. We compared survival outcomes according to the criteria of the European Organization for Research and Treatment of Cancer (EORTC), PERCIST 1.0, the Peter Mac metabolic visual criteria, and the Deauville criteria, respectively. Methods: Three prospective trials of chemoradiation for NSCLC, involving baseline and posttreatment 18 F-FDG PET/CT imaging, were conducted between 2004 and 2016. Responses were categorized as complete metabolic response (CMR), partial metabolic response, stable metabolic disease, or progressive metabolic disease. Cox proportional-hazards models and log-rank tests assessed the impact of each response on overall survival (OS). Results: Eighty-seven patients underwent 18 F-FDG PET/CT before and after radical chemoradiation for NSCLC. Follow-up 18 F-FDG PET/CT scans were performed at a median of 89 d (interquartile range, 79-93 d) after radiotherapy. Median follow-up and OS after PET response imaging were 49 and 28 mo, respectively. Interobserver agreements for EORTC, PERCIST, Peter Mac, and Deauville had κ values of 0.76, 0.76, 0.87, and 0.84, respectively. All 4 response criteria were significantly associated with OS. Peter Mac and Deauville showed better fit than EORTC and PERCIST and distinguished better between CMR and non-CMR. Conclusion: All 4 response criteria were highly predictive of OS, but visual criteria showed greater interobserver agreement and stronger discrimination between CMR and non-CMR, highlighting the importance of visual assessment to recognize radiation pneumonitis, changes in lung configuration, and patterns of response., (© 2019 by the Society of Nuclear Medicine and Molecular Imaging.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results